2012-10-18 12:54:29 - The global HGH report discusses the key ongoing trends like licensing agreement, development of needle free injectors and comparison between generic and biosimilar drug versions. On the industry development front, the current inclination is towards creating innovative therapeutic products with novel properties. Furthermore, the major factors driving the HGH market include rising cancer and CKD/ESRD cases and increasing GNI and healthcare expenditure on worldwide basis. In addition, a few factors posing challenges in front of the HGH industry are the off-label HGH use, associated risks and side effects and the escalating price pressure which, to an extent, are hindering the growth and development of the same.

Pituitary- the master gland of human body is responsible for controlling crucial hormonal secretion which in turn regulates other key aspects of human body such as temperature, growth, thyroid functioning, urination and production of other hormones. It is a pea sized gland situated at the base of brain and is a major component of human body as it expedites the response towards the surrounding environment and settings.

Any deformity or damage to the pituitary gland can adversely impact the production and activity level of the above mentioned hormones thereby affecting the body work process and stunting the outcomes especially in the case of growth hormone. Marred pituitary function leads to either over or under secretion of the somatrpopin that is the

growth hormone. Its over secretion causes disfiguration in the body parts like hands, face, feet etc. whereas its deficiency impedes the growth of body parts/whole body thus leading to disease states like dwarfism or gigantism.

It is observed that the growth hormone related problems usually affect children and teenagers, but it is seen to grip adults as well but to a lesser extent. The major factors which vitiate the pituitary operations thus impairing the GH role include kidney malfunction, tumors/cancer especially associated with brain. There are some other unknown causes as well which are termed as idiopathic. Earlier, to deal with these predicaments, growth hormone (GH) used to be extracted from the human cadavers but, as time passed and evolution of technology/tools/techniques/R&D took place, the extraction of GH also got altered and many novel innovations and discoveries were made in the respective field.

The report consists of the following sections:-

1. Human Growth Hormone

1.1 Physiological Effects of Growth Hormone
1.2 GH Secretion Control
1.3 GH Deficiency (GHD)
1.4 Therapeutic and Other Uses of GH/HGH
1.5 Recombinant Human Growth Hormone (rHGH)

2. Global HGH Market Size

2.1 HGH-CTP Market Opportunity Model
2.2 SRhGH Market Opportunity Model

3. Market Dynamics

3.1 Key Trends
3.2 Industry Developments
3.3 Growth Drivers
3.4 Challenges

4. Competitive Landscape

5. Company Profiles

5.1 Roche Holdings AG
5.2 Novo Nordisk
5.3 Pfizer, Inc.
5.4 Eli Lilly and Company

6. Market Outlook

6.1 Market Forecast
6.2 Forecast Methodology

List of Charts

GH’s Physiological Effect
GH Secretion Control
Global HGH Market Share (2010)
Global Human Growth Hormone Market (2004-2010)
Global hGH-CTP Market Opportunity (2014E-2020E)
Market Share of Chemical Drugs and Biologics as per Drug Versions
Number of Cancer Cases Worldwide (2007-2011)
Worldwide Patients with End Stage Renal Disease (2005-2011)
Global Healthcare Spending (2005-2015E)
World Gross National Income (2005-2010)
Growth Hormone Volume Market share (February 2007-February 2012)
Roche’s Revenues by Business Segments (2011)
Roche’s Revenues and Net Income, 2007-2011
Novo Nordisk Revenue Share by Business Segments (2011)
Novo Nordisk Revenues & Net Income (2008-2011)
Pfizer’s Revenue Share by Business Segments (2011)
Pfizer’s Revenues & Net Income (2008-2011)
Eli Lilly’s Revenues by Segment (2011)
Eli Lilly’s Revenue and Net Income (2008-2011)
Global HGH Market Forecast (2009-2014E)

List of Tables

Worldwide Revenues of Marketed hGH Products (2011)
hGH-CTP US Market Opportunity Model (2014E-2020E)
hGH-CTP European Market Opportunity Model (2014E-2020E)
SRhGH Market Opportunity Model (2013E-2020E)
Annual US Sales of rHGH and Injectors
LG Life Sciences Product under Development
Sustained-release HGH under Development Worldwide
Prolor’s Product under Development
GH Products Devised by NovoNordisk
Growth Hormone Volume Market share (February 2007-February 2012)
Dependent & Independent Variables (2006-2011)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

For further details, kindly visit konceptanalytics.com/reportDetail.aspx?reportID=421